Tony Gibney Photo April 2024
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
16 avr. 2024 07h05 HE | Clearside Biomedical, Inc.
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
ocugen_4C_LOGO (002).png
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
08 avr. 2024 06h30 HE | Ocugen
MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
ocugen_4C_LOGO (002).png
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
05 avr. 2024 07h02 HE | Ocugen
Established Low Dose as Safe and Tolerable Dose in Current OCU410 Clinical TrialDSMB Approval to Proceed with Medium Dose Cohort Dosing Malvern, Pa., April 05, 2024 (GLOBE NEWSWIRE) -- Ocugen,...
ocugen_4C_LOGO (002).png
Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023
01 avr. 2024 17h43 HE | Ocugen
MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval
PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval
18 mars 2024 14h37 HE | PRISM MarketView
PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval
Lipella Pharmaceuticals was recently granted Orphan Drug Designation by the FDA for LP-410
PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease
07 mars 2024 15h23 HE | PRISM MarketView
PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease
finacialnews-logo-final-01 (2).png
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
05 mars 2024 08h30 HE | FN Media Group LLC
PALM BEACH, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is one of the leading causes of cancer death globally. The increasing incidence of this cancer...
Transparency Market Research
Biopharmaceutical Fermentation Systems Market Projected to Reach USD 52.6 billion by 2031, with a CAGR of 9.5%: Report by Transparency Market Research Inc.
01 mars 2024 01h32 HE | Transparency Market Research
Wilmington, Delaware, United States, March 01, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global biopharmaceutical fermentation systems market is projected to grow at a CAGR of...
PMV main logo.png
PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day
29 févr. 2024 09h54 HE | PRISM MarketView
PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day
ocugen_4C_LOGO (002).png
Ocugen Clinical Showcase Webcast Now Available
28 févr. 2024 08h00 HE | Ocugen
MALVERN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...